MiMedx Group (NASDAQ:MDXG) Hits New 12-Month Low – Here’s What Happened

MiMedx Group, Inc (NASDAQ:MDXG)’s share price reached a new 52-week low on Wednesday . The stock traded as low as $5.65 and last traded at $5.7040, with a volume of 235734 shares trading hands. The stock had previously closed at $5.88.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Mizuho cut their price target on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 17th. Finally, Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and a consensus price target of $11.00.

MiMedx Group Stock Down 3.7%

The company’s fifty day simple moving average is $6.91 and its 200-day simple moving average is $6.93. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. The firm has a market capitalization of $838.99 million, a PE ratio of 20.98 and a beta of 1.57.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.08. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The company had revenue of $113.73 million for the quarter, compared to analyst estimates of $94.74 million. On average, analysts forecast that MiMedx Group, Inc will post 0.3 EPS for the current year.

Insider Activity at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the sale, the insider owned 236,982 shares in the company, valued at $1,758,406.44. This represents a 19.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On MiMedx Group

Several hedge funds have recently modified their holdings of the company. CWM LLC grew its stake in MiMedx Group by 63.8% in the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after acquiring an additional 1,892 shares during the period. Rhumbline Advisers increased its position in shares of MiMedx Group by 1.4% during the first quarter. Rhumbline Advisers now owns 177,156 shares of the company’s stock worth $1,346,000 after purchasing an additional 2,436 shares in the last quarter. Legato Capital Management LLC raised its stake in MiMedx Group by 18.5% in the 3rd quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock valued at $121,000 after purchasing an additional 2,708 shares during the last quarter. HighMark Wealth Management LLC lifted its holdings in MiMedx Group by 5.4% in the 3rd quarter. HighMark Wealth Management LLC now owns 55,878 shares of the company’s stock valued at $390,000 after purchasing an additional 2,878 shares in the last quarter. Finally, SkyView Investment Advisors LLC boosted its stake in MiMedx Group by 3.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after purchasing an additional 3,032 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.